


Accepted Manuscript

Food, Immunity, and the Microbiome

Herbert Tilg, Alexander R. Moschen



PII: S0016-5085(15)00012-8
DOI: [10.1053/j.gastro.2014.12.036](https://doi.org/10.1053/j.gastro.2014.12.036)
Reference: YGAST 59530

To appear in: *Gastroenterology*
Accepted Date: 23 December 2014

Please cite this article as: Tilg H, Moschen AR, Food, Immunity, and the Microbiome, *Gastroenterology* (2015), doi: 10.1053/j.gastro.2014.12.036.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

All studies published in *Gastroenterology* are embargoed until 3PM ET of the day they are published as corrected proofs on-line. Studies cannot be publicized as accepted manuscripts or uncorrected proofs.

Food, Immunity, and the Microbiome

Running title: Diet and microbiome

Herbert Tilg* and Alexander R Moschen

Department of Internal Medicine I

Endocrinology, Gastroenterology & Metabolism

Medical University Innsbruck, Austria

**Corresponding author:*

Herbert Tilg, M.D., Department of Internal Medicine I, Gastroenterology, Endocrinology & Metabolism, Medical University Innsbruck, Innsbruck, Austria

Phone: +43 512 504 23539, Fax: +43 512 504 23538

E-mail: herbert.tilg@i-med.ac.at

HT and ARM certify that there is no conflict of interest.

This work has been supported by the Tyrolean Science Fund UNI-0404-1480 (to ARM).

Key words: anti-inflammatory, inflammation, malnutrition, metabolome, Western diet

Abstract

There is increasing evidence that ingested diet-borne components are involved in the pathogenesis of disorders such as inflammatory bowel diseases, atherosclerosis, and type-2-diabetes. Nutrients can have short- and long-term effects in shaping the composition of the microbiota. Western diets (enriched in fat, phosphatidylcholine, and L-carnitine) promote inflammation and atherosclerosis through specific fatty acids and degradation products such as trimethylamine N-oxide. Other dietary factors such as carbazoles or tryptophan-enriched proteins have anti-inflammatory properties—partly via activation of aryl hydrocarbon receptors. The microbiota and its metabolic machinery produce a myriad of metabolites that serve as important messengers between the diet, microbiota, and host. Short-chain fatty acids affect immune responses and epithelial integrity via G-protein coupled receptors and epigenetic mechanisms. By increasing our understanding of interactions between diet, immunity, and the microbiota, we might develop food-based approaches to prevent or treat many diseases. There is now scientific evidence to support the adage “we are what we eat”, and this process begins in early life.

The human gastrointestinal tract harbors more than 100 trillion bacteria that, together with archaea, fungi, and viruses, form the gut microbiota. The cumulative collection of genetic information extractable from the microbiota is astonishingly diverse¹⁻⁴ The microbiota colonizes our intestine with increasing densities, reaching up to 10^{11} bacteria/g of luminal content in the colon. Not surprisingly, the human microbiome includes a huge amount of genetic information—100-fold more genes than the human genome. With this enormous pool of genetic information, the microbiota may influence human life at many levels, far beyond host immunity and metabolic functions.

Studies on the human microbiota have been catalyzed by the availability of feasible diagnostic tools. Most studies have tried to categorize the microbiota according to operational taxonomic units, based sequence analyses of variable regions of bacterial 16S ribosomal DNA genes. More elaborate metagenomic studies aim to generate a map of the entire metagenome, from which functional properties can be inferred. High degrees of bacterial richness and diversity have been associated with good health.⁵

As we have increased our knowledge about the dynamics of microbial compositions, we have identified numerous variables that can be used to determine the composition of the microbiota. Diet has emerged probably as the most relevant factor. By the time children reach 3 years of age, their microbiota resemble that of adults; studies have shown that besides mode of childbirth, severe illnesses and antibiotic therapy, and particularly the diet, affect colonization patterns of the infant's microbiota in early life.^{4, 6, 7} Although the effects of breast- vs. formula-feeding seem to be important, the greatest change in microbial composition occurs with the introduction of solid foods, again pointing to diet as a central determinant of the microbiota.⁸⁻¹⁰ Recent studies have demonstrated that certain diets may

induce short-term reversible and others long-term effects which may persist throughout life.^{5, 11}

The microbiota is an important factor in human development and maintenance of the immune response. Diet determines its dynamics and composition, and the triad diet–microbiota–immunity is required for human development and health. Recent increases in the incidence of insulin resistance, type 2 diabetes, inflammatory bowel disease (IBD), asthma, and various cancers have been linked to changes in diet, immunity, and microbiota.¹² Diets such as a Mediterranean diet have been proposed to provide health benefits.¹³ We review the effects of food on the microbiome and thereby on host immunity, discussing pathways that might mediate the beneficial or detrimental effects of various diets and food components.

Diet and the Microbiome

There are different effects of diet on the structure of the intestinal microbiota.^{14, 15} There is growing evidence that recent lifestyle changes, most notably high-fat and high-sugar Western diets, have had substantial effects on taxonomic, genetic, and metabolic features of our microbiota.^{16, 17} These manipulations of the microbiota might contribute to the growing epidemics of chronic diseases such as allergy, IBD, atherosclerosis or obesity and type 2 diabetes.¹⁸

The first evidence for the effects of diet on the human GI microbiota came from a study that compared the microbiomes of rural African and Italian children.¹⁹ Analyses of stools from African children showed a significant depletion in *Firmicutes* and *Enterobacteriaceae* (*Shigella* and *Escherichia*), and significantly more short-chain fatty

acids (SCFA), compared to Italian children. The *Bacteroides* enterotype observed in children from Florence correlated with consumption of animal protein, a variety of amino acids, and saturated fats; meat consumption, a feature of the Western diet, was likely to have contributed to this enterotype. The authors concluded that a Western lifestyle, which also includes clean water and refrigerated western foods, resulted in the dominance of *Bacteroides*, whereas an African lifestyle, characterized by home-made vegetarian, high-fiber containing foods, resulted in the dominance of *Prevotella* in the microbiota. However, it is not clear whether these findings are clinically relevant, and the concept of enterotypes has not been fully established.²⁰

Zimmer et al compared microbial compositions in fecal samples from vegetarians and vegans with those of similar number of omnivores.²¹ They reported that proportions of *Bacteroides* spp., *Bifidobacterium* spp., *Escherichia coli*, and *Enterobacteriaceae* spp. were significantly lower in samples from vegans than from omnivores. Proportions of *E coli* biovars, *Klebsiella* spp., *Enterobacter* spp., other *Enterobacteriaceae*, *Citrobacter* spp., and *Clostridium* spp. did not differ between the groups. The proportions of these microbes in vegetarians were between those of vegans and omnivores.²¹

Preclinical studies have also shown that different diets affect the microbiota. A high-fat diet (HFD) alters the composition of the intestinal microbiome of mice independently of obesity.²² Placing mice on HFDs reduced proportions of *Bacteroidetes* and increased those of *Firmicutes* and *Proteobacteria*. Turnbaugh et al transplanted fresh or frozen adult human fecal preparations into germ-free C57BL/6 mice. These so-called humanized mice were stably colonized and had the same levels of bacterial diversity as their donors, demonstrating the ability of the microbiota to establish a stable ecosystem in a competitive

environment.¹⁶ Switching these mice from a low-fat, plant polysaccharide-based diet to a high-fat, high-sugar-containing (Western) diet altered their microbial structures within 24 hours. The microbiota had changes in predominant metabolic pathways and patterns of gene expression. These findings indicate that changes in the microbiota occur due when certain bacteria are able to bloom in a new environment.¹⁶

Walker et al also provide evidence that dietary modifications can have rapid effects on the microbiota.²³ The short-term effects of controlled macronutrients were studied in 14 overweight men who received diets either entirely of animal or plant products for 10 weeks. Diets high in resistant starch (the plant product diet), an important non-digestible carbohydrate, increased proportions of *Firmicutes* bacteria related to *Ruminococcus bromii* within 3–4 days, although these changes could be rapidly reversed.²³ Short-term dietary interventions are able to modify the microbiota substantially and rapidly, as shown by David et al.¹⁷ Here, an animal-based diet changed the microbiota in only a single day. The most significant changes observed were within the clusters *Bilophila wadsworthia*, *Alistipes putredinis*, and *Bacteroides* sp., which are all involved in bile resistance. These findings support the link between dietary saturated milk fats, bile acids, and outgrowth of inflammatory bacteria such as *Bilophila wadsworthia*. They also show that the human gut microbiome can adapt rapidly to herbivorous and carnivorous diets.

Exercise and age can also affect the relationship between microbiota, immunity, and metabolism. Clarke et al studied the effects of exercise and diet on the intestinal microbiota by analyzing fecal samples from male professional rugby players and healthy male controls (non-athletes). Healthy male control groups with different BMIs (BMI < 25 vs > 28), were included to control for age, diet, and level of physical activity. Exercise increased the

diversity of the microbiota as well as protein consumption, which was significantly higher in athletes compared to controls. There was a positive correlation between protein intake and microbial diversity.²⁴

Studies of the microbiota of an elderly population showed that they have greater levels of inter-individual variation than among younger adults.²⁵ Claesson et al correlated microbial composition with measures of frailty, co-morbidities, inflammation, and nutritional status, indicating the relevance of the GI microbiota to human health.⁵ In this study, residents of a long-term facility had increased proportions of *Prevotella*, *Ruminococcus*, *Alistipes*, and *Oscillobacter*, compared to non-residents. However, as for many studies comparing the microbiomes of different populations,²⁶ correlations do not indicate causation—it could be that poor health in this elderly population affected their GI microbiome.

Recent studies have associated the intestinal microbiota with the efficiency in producing energy from diet, which might affect body weight, development of obesity, and related disorders such as non-alcoholic fatty liver disease.^{27, 28} Most studies have focused on the effects of dietary excess and obesity-related disorders on the microbiota;²⁹ this topic is not covered by this article (for reviews, see³⁰⁻³²). Although many studies have provided evidence for the effects of diet on the microbiota, more high-quality studies are needed to determine how these changes affect human health. There are many confounding factors to analyses of the human microbiota, and it is difficult to determine which differences have clinical relevance. Relationships among food, immunity, and the microbiota are presented in Figure 1.

Mechanisms of Inflammatory Diets

Epidemiologic features of many chronic inflammatory disorders have changed dramatically in the last 30 years. Disorders such as IBD, rheumatoid arthritis, metabolic syndrome, and atherosclerosis, are characterized by continuous low-grade systemic inflammation, of unknown causes. Genetic factors contribute, to various degrees, to some of these diseases, such as IBD.³³ Epidemiologic studies, however, have indicated that environmental factors such as diet also have important roles. Diet can directly affect inflammatory processes and the immune system, and also through mechanisms involving the microbiota. The definition of gut health varies and depends on ethnic, genetic, geographical, and dietary factors that maintain a delicate balance between food, the microbiota, and immunity. Disruption of this homeostasis balance can initiate metabolic and/or inflammatory diseases.³⁴

Western diets have long been assumed to promote inflammatory processes. Rural Africans consume substantially more fiber than people in Western countries and rarely develop diseases such as allergy, asthma, colon cancer, or cardiovascular diseases.³⁵ The Western diet comprises refined grains, alcohol, salt, certain oils, corn-derived fructose, fatty domesticated meats, and other foods, frequently consumed in caloric excess. It can be further characterized by increased consumption of energy-dense, processed foods and reduced consumption of vegetables and fruits.

Several of these constituents, such as fructose, have been associated with development of chronic inflammatory disorders.^{36, 37} Excessive consumption of sodium has long been associated with conditions such as arterial hypertension.³⁸ However, excessive sodium consumption also affects intestinal immunity and inflammation, by induction of interleukin-17 (IL17)-producing T helper cells, although this study did not explore the role of

the microbiota in this process.³⁹In contrast, a Mediterranean diet, characterized by high consumption of vegetables, olive oil, and fruits, is associated with lower rates of cardiovascular diseases and asthma.^{13, 40}There is increasing evidence that the composition of the gut microbiota, as affected by various diets, is related to disease development.⁴¹

Metabolites of dietary phospholipid phosphatidylcholine (PC)

There have been recent major advances in our understanding of the relationship among the metabolome, the microbiota, and cardiovascular disease.⁴² Researchers searched for cardiovascular risk factors using a metabolomic approach, and identified metabolites derived from dietary phospholipid phosphatidylcholine (PC): choline, trimethylamine (TMA) N-oxide, and betaine. PC (also called lecithin) is enriched in foods such as red meat, eggs, milk, and certain fish. It is converted towards choline and TMA by enzymes produced by the gut flora.⁴³TMA is further metabolized by hepatic flavin monooxygenases (FMO) to TMA N-oxide (TMAO).⁴⁴Wang et al demonstrated that generation of TMAO requires the microbiota, does not occur in germ-free mice, and can be prevented by administration of antibiotics.⁴²Then, in a large series of patients, they showed that levels of choline, betaine, and TMAO correlated with all cardiovascular disease phenotypes. This was the first published link among diet, the microbiota, and an inflammatory disease (atherosclerosis can be considered an inflammatory disorder).

In support of this observation, atherosclerosis-prone *ApoE*^{-/-} mice develop significantly more atherosclerotic plaques than wild-type mice when placed on diets enriched in PC. In humans, Wang et al observed an association between circulating concentrations of TMAO and hepatic expression of a flavin-containing monooxygenase 3 (FMO3, a transmembrane drug-metabolizing enzyme); there could be

inter-individual differences in TMAO levels based on expression of FMO3.⁴² Mouse FMO3 has 10-fold higher specificity than FMO1 for TMA, and mice that overexpress FMO3 have increased levels of TMAO.⁴⁵ Diets enriched in choline and TMA increased formation of peritoneal macrophage foam cells, macrophage cholesterol content, numbers of aortic macrophages, and expression of the scavenger receptor CD36 in mice.

Increasing our understanding of the relationship among food, microbiota, and disease could lead to treatments that involve functional foods or pre- or probiotics.⁴⁶ Interestingly, certain methanogens, which are variably present in human gut, use only methyl compounds including TMA as substrates. One of these strains, *Methanomassiliicoccus luminyensis* 10 can deplete TMA by reducing it with H₂ for methanogenesis.⁴⁷

In a study of 4007 participants, levels of TMAO correlated with major adverse cardiovascular events—even after adjustment for conventional risk factors.⁴⁸ In the same study, levels of TMAO were substantially reduced by administration of broad-spectrum antibiotics to healthy participants who consumed 2 hard-boiled eggs. A recent study by the same authors associated increased plasma levels of choline and betaine with major adverse cardiac events, although when levels of TMAO were also increased.⁴⁹ It is unclear whether these events are associated with genetic factors. A recent study suggested that nutritional factors might have stronger effects than genetic factors in determining TMAO levels.⁵⁰

There are high levels of another TMA, L-carnitine, in red meat. It is also processed by the gut microbiota, results in increased levels of TMAO, and is associated with atherosclerosis.⁵¹ A continuous diet high in L-carnitine caused large changes in the coecal microbiota of mice, leading to increased plasma levels of TMAO and atherosclerosis. This

process was microbiota-dependent and in humans increased plasma levels of L-carnitine correlated with cardiovascular events—again only in association with increased levels of TMAO. Interestingly, vegans and vegetarians produced less TMAO from L-carnitine than omnivores.⁵¹ Dietary L-carnitine also promoted atherosclerosis in *ApoE*^{-/-} mice.⁵¹ Many studies have therefore associated dietary PC and L-carnitine consumption with the activities of the microbiota and cardiovascular disease. These types of findings offer exciting new insights as to how a Western diet might promote cardiovascular and other diseases.

Fat

The Western diet might have other features that contribute to its inflammatory effects—especially high fat content. Fatty acids promote inflammation through diverse mechanisms, including direct actions on immune cells, toll-like receptors (TLRs), and cytokine signaling, as well as by affecting intestinal permeability.⁵²⁻⁵⁴ Even in healthy subjects, a high-fat Western diet was correlated with endotoxemia and may contribute to a state of systemic low-grade inflammation.^{55, 56} A HFD induced intestinal inflammation, increasing ileal production of tumor necrosis factor and adiposity, only in conventionally raised specific-pathogen free mice, but not germ-free mice.⁵⁷ A HFD, but not a low-fat diet, resulted in severe pulmonary damage and mortality in mice with combined disruption of *Tlr2* and *Tlr4*. This phenotype was transmissible to wild-type mice upon either cohousing or fecal transplantation; antibiotics prevented pulmonary disease, indicating the involvement of certain pathobionts.⁵⁸

The Western diet is commonly enriched in polyunsaturated fatty acids such as n-6. A diet rich in polyunsaturated fatty acids led to intestinal inflammation in older mice, demonstrated by increased influx of neutrophils and macrophages, and was associated dysbiosis, with depletion of *Bacteroidetes* and *Firmicutes*.⁵⁹ A 3-week diet of saturated milk-derived fatty acids, but not polyunsaturated fat or a low-fat diet, increased formation of taurin-conjugated bile acids (e.g. taurocholic acid) in *IL10*^{-/-} mice which develop spontaneous colitis.⁶⁰ These alterations in bile composition increased the availability of organic sulphur in the intestinal lumen, leading to expansion of the low-abundance, sulphite-reducing pathobiont *Bilophila wadsworthia* in vitro and in vivo. This resulted in increased susceptibility and severity of colitis in IL10-deficient, but not wild-type, mice via an increased T-helper 1 cell response. Interestingly, mono-colonization of germ-free IL10-deficient mice with *B. wadsworthia* led to colitis only in association with the consumption of milk fatty acids. These findings support the association of certain dietary fats contained in Western diets with dysbiosis and development of colitis, and indicate the diet-induced expansion of certain pathobionts.⁶⁰

Pups from female mice fed HFDs during gestation and lactation had worse outcomes in various models of immune-mediated inflammation.⁶¹ For example, they had increased colonic inflammatory responses, higher circulating concentrations of endotoxin, and alterations to the microbiome. These findings indicate that an altered microbiota can be inherited.

Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) is overexpressed on the surface of ileal mucosa in patients with Crohn's disease and acts as a receptor for adherent invasive *E. coli* (AIEC). Wild-type mice and mice that overexpress

CEACAMs 3, (5), 6, or 7, when placed onHFDs, developed alterations to their intestinal microbial community structures,with increases in mucus-degrading *Ruminococcus torques* and *Bacteroides* and *Prevotell*species.⁶² Findings were paralleled by changes in intestinal permeability and goblet cell number and activation of different immune pathways, allowing AIEC to adhere. Therefore, diet cannot only affect the microbiota but also changes its behavior toward a disease promoting directionparticularly in genetically susceptible hosts.

Overall, Western diets have been shown to affect immunity, promote inflammation, and alter the microbiota and metabolomevia different pathways, with major health implications (Table 1, Figure 2).

Protective Interactions Among Diet, Immunity, and the Microbiota

Diets enriched in vegetables and fruits seem to contribute to GIhomeostasis and have anti-inflammatory effects. Aryl hydrocarbon receptor (AhR), a transcription factor expressed byimmune cells, epithelial cells, and some tumor cells, is an important receptor for certain dietary components. There are multiple exogenous and endogenous AhR ligands—some come from foods such as broccoli, others include phytochemicals, natural chemicals, and bacterial metabolites. Ligand binding activates the AhR, causing its translocation into the nucleus, where it dimerizes with the AhR nuclear translocator. This heterodimer regulates many genes that control immunity and inflammation, such as *IL22*.

Two studies demonstrated how dietary-derived AhR ligands affect local immunity and the microbiota.^{63, 64} Specific components of certain vegetables of the family Brassicaceae (for example, broccoli or cabbage) are physiologic ligands of the AhR. Li et al showed that AhR signaling helps maintain intraepithelial lymphocytes, and that AhR-

deficiency increased epithelial vulnerability and immune activation in mice. AhR-deficient mice had alterations to the composition of their microbiota, and decreased intestinal production of granzymes A and B, C-type lectins, and matrix metalloproteinase 7, accompanied by a 4-fold increase in the proportion of *Bacteroidetes*. Interestingly, absence of AhR ligands increased severity of colitis in mice; when these mice were placed on diets enriched in AhR ligands, observed alterations were partly reversed.

Kiss et al demonstrated that activation of AhR by dietary ligands is required for post-natal expansion of certain innate lymphoid cells and the development of intestinal lymphoid follicles.⁶⁴ Mice deficient in AhR had an impaired immune response and were highly susceptible to infection with *Citrobacter rodentium*. AhR ligands increased numbers of IL22-producing ROR γ ⁺ intestinal lymphoid cells. These cells help coordinate intestinal epithelial innate immune functions such as the production of anti-microbial peptides and mucus and maintenance of epithelial integrity. Numerous studies have shown that AhR is required for production of IL22, supporting the importance of this relationship.⁶⁵ The studies of Li et al and Kiss et al provide evidence that some sort of dietary pattern recognition receptors might exist that link diet with intestinal immunity and the microbiota.

AhR expression is decreased in intestinal tissue of patients with IBD, and activation of AhR signaling by specific agonists reduces colitis.⁶⁶ The pathway between AhR ligands and IL22 may be of major interest beyond the field of intestinal immunity. Administration of IL22 reduced metabolic defects and restored mucosal immunity to mice on HFDs, as well as in leptin receptor-deficient (*db/db*) mice.⁶⁷ Commensal bacteria such as *Clostridia* have the potential to protect against food allergen sensitization, by inducing production of IL22.⁶⁸ So, dietary factors that activate the AhR have the capacity to affect expression of cytokines

(particularly IL22), synthesis of mucins, production of antimicrobial peptides, and consequently shape the composition of the intestinal microbial community (see Figure 3).

AhR binding of specific ligands such as 6-formylindolo(3,2-b) carbazole increases natural killer cell activation, including production of interferon- γ and cytolytic activity.⁶⁹ Administration of AhR ligands to mice increased the ability of natural killer cells to control growth of a murine lymphoma cell line (RMA-S cells) and RMA-S-induced tumor formation. Another fascinating aspect of AhR is that some of its ligands are bacterial metabolites.⁷⁰ 1,4-dihydroxy-2-naphthoic acid, a precursor to vitamin K2 produced from *Propionibacterium freudenreichii* and isolated from Swiss-type cheese, activated AhR in vitro and in mice, increasing synthesis of antimicrobial peptides, altering gut microbiota and reducing dextran sulfate sodium-induced colitis. Bacterial pigments, namely phenazines (*Pseudomonas aeruginosa*) and naphthoquinone phthiocol (*Mycobacterium tuberculosis*), are also direct activators of AhR that control anti-bacterial responses.⁷¹ The AhR is therefore unique in that it is not only a dietary pattern recognition receptor, but also as a pathogen-associated molecular pattern receptor.

The essential amino acid tryptophan is another nutrient that might have anti-inflammatory activities. As found in various vegetables and fish, tryptophan is metabolized by the microbiota, e.g. *Lactobacilli*, to indole-3-aldehyde, another AhR agonist.⁷² Switching the diet from sugar to tryptophan as major energy source resulted in expansion of *Lactobacilli* that produce the AhR ligand indole-3-aldehyde. This interaction was accompanied by induction of IL22, which affected the microbiota, providing resistance to colonization by *Candida albicans* and protecting the mucosa against inflammation.

Beside the well-established function of angiotensin-converting enzyme 2 (ACE2) in the renin-angiotensin-system (RAS), ACE2 also regulates intestinal amino acid homeostasis and expression of antimicrobial peptides, affecting the gut microbiome. ACE2-dependent changes in epithelial immunity and the gut microbial communities might depend on dietary tryptophan.⁷³ Tryptophan might exert anti-inflammatory effects via additional pathways such, as after conversion to kynurenine by indoleamine 2,3-dioxygenase (IDO). Both kynurenine and IDO have immunomodulatory functions that include promotion of regulatory T cells and regulation of immune tolerance.⁷⁴

Not unexpectedly, the tryptophan metabolite kynurenine is another tryptophan-derived ligand of the AhR. Kynurenine is produced by cancer cells and suppresses anti-tumor immune responses.⁷⁵ Tryptophan metabolites such as kynurenic acid and niacin also interact with certain G-protein coupled receptors (GPCRs). Beside carbazoles or indole-3-aldehyde, several other plant products, such as flavonoids and polyphenols, also bind the AhR—although with lower affinity.^{76, 77} The AhR might therefore be considered as to be a major anti-inflammatory factor that integrates dietary (dietary pattern recognition receptors), microbial, metabolic, and endogenous signals to alter the composition of the microbiome and elicit protective immune reactions (Table 1 and Figure 3).

Short-chain Fatty Acids (SCFAs)

One mechanism by which the gut microbiota promote GI homeostasis is likely to involve production of the SCFAs acetate, butyrate, and propionate. These molecules serve as messengers that link dietary fiber to the commensal microbiota and the host. Although there is little evidence for how certain commensals contribute to production of various

metabolites, including SCFAs, diet substantially affects fecal SCFA content. Contingent on a fiber-rich diet, African children have much higher fecal concentrations of SCFAs than European adolescents.¹⁹ Dietary fibers come from the indigestible part of plant foods and contain either insoluble fiber, such as cellulose or lignin, or soluble fiber, such as galacto- or fructo-oligosaccharides. Only soluble fibers are digested by microbiota-derived enzymes into large quantities. Notably, SCFAs provide approximately 5%–10% of total energy to healthy people. SCFAs diffuse passively and distribute systemically, are recovered via mono-carboxylic-acid transporters. However, they might mostly act as signaling molecules by binding to various GPCRs, such as GPR41 (free fatty acid receptor 3, FFAR3) and GPR43 (FFAR2), or GPR109A.^{78, 79} GPCRs are found in many different cell types, including gut epithelial cells, adipocytes, and immune cells such as macrophages or dendritic cells.

SCFAs, Nicotinic Acid, GPCRs, and the Intestinal Immune System

SCFAs, along with other metabolites produced in the intestine, help maintain gut homeostasis and epithelial integrity by processes that might include mucus production, secretion of immunoglobulin A, and tissue repair. The acetate-producing commensal *Bacteroides thetaiotaomicron* induces goblet cell proliferation and mucus production.⁸⁰ Similar functions have been shown for other protective commensals, such as *Faecalibacterium prausnitzii*. An intact mucus layer is required for intestinal function; its disruption is likely to initiate intestinal disorders such as ulcerative colitis, as well as extra-intestinal diseases.

SCFAs also have many anti-inflammatory activities, such as suppression of inflammatory cytokines and chemokines,⁸¹ and reduce production of adhesion molecules,

probably by pathways that lead to inactivation of NF κ B.⁸² Furthermore, SCFAs may directly interfere with inflammasomes and cytokines such as IL18 or IL22, which have important roles in maintaining epithelial integrity.⁸³ Depletion of acetate-producing *Bifidobacteria* increased susceptibility to enteropathogenic infections and promoted excessive intestinal inflammation in mice.¹⁰

GPCRs can sense metabolites to activate signaling pathways, and research into their roles in GI homeostasis and intestinal immunity is moving rapidly.⁸⁴ They frequently signal via arrestin β 2⁸⁵, and GPR43, GPR109A (HCAR2), and GPR120 have anti-inflammatory effects. Mice deficient in GPR43 have exacerbated inflammatory reactions in several organs including the intestine,⁸⁶ an effect probably mediated by lack of acetate. GPR120 binds Ω -3 fatty acids to protect against inflammation and has metabolically beneficial effects.⁸⁵

Ω -3 fatty acids are key components of healthy diets such as the Mediterranean diet and suppress inflammation in humans.⁸⁷ It remains to be established if and how Ω -3 fatty acids affect the microbiota. Activation of GPR109A, a receptor for butyrate and nicotinic acid (niacin), a vitamin, and a degradation product of tryptophan, can prevent colonic inflammation and tumorigenesis.⁸⁸ Activation of GPR109A resulted in increased expression of anti-inflammatory molecules in macrophages and dendritic cells, induced development of regulatory T cells, and stabilized the gut barrier by upregulating IL18.⁸⁸ Therefore, GPR109A seems to interact with bacteria-derived metabolites to prevent or reduce inflammation. Findings from studies of nicotinic acid are exciting, as it blocks production of inflammatory cytokines, activation of macrophages,⁸⁹ and atherosclerosis in mice and humans.⁹⁰

SCFAs and Systemic Immunity

Butyrate induces differentiation of colonic regulatory T cells and prevents development of colitis in mice following administration of CD4⁺CD45RB^{hi} cells. Interestingly, there is a correlation between butyrate content in the gut and numbers of regulatory T cells.⁹¹ Butyrate increased acetylation of histone H3 at the promoter of the gene encoding the forkhead transcription factor FOXP3, providing some interesting clues for potential mechanisms. In addition, butyrate and propionate each facilitate development of regulatory T cells outside the thymus; this activity involved their ability to inhibit histone deacetylases (HDAC), an anti-inflammatory effect.

Acetate does not induce development of regulatory T cells or inhibit HDAC.⁹² These findings support those from a study showing that SCFAs control the development of colonic regulatory T cells in a GPR43-dependent manner.⁹³ Butyrate might regulate intestinal macrophage function by preventing production of inflammatory cytokines, also in an HDAC-dependent manner.⁹⁴ By these mechanisms, SCFAs could help maintain tolerance to the intestinal microbiota and reduce the responsiveness of lamina propria mononuclear cells. Induction of regulatory T cells might be one mechanism by which SCFAs promote tolerance to the microbiota. Mice fed high-fiber diets undergo alterations to the intestinal microbiota and are then protected from allergic airway inflammation.⁹⁵ The SCFA propionate regulates allergic inflammation, bone marrow hematopoiesis, dendritic cell and macrophage functions, via GPCRs—in the case of the high-fiber diet, via GPR41.

So, SCFAs are not only an important energy source, but also act as signaling molecules, particularly in the intestine, where they maintain energy balance and epithelial

integrity. GPCRs are activated in response to nutrients beyond SCFAs, such as tryptophan or tryptophan metabolites such as nicotinic acid, Ω -3 fatty acids, and kynurenic acid (see Figure 3). Nonetheless, the picture is far from complete, as certain GPCRs such as GPR91 have inflammatory activity upon binding to succinate.⁹⁶

Under-nutrition, Immunity, and Alterations to the Microbiota

Just as obesity is associated with changes to the microbiota,³² so is malnutrition. Severe acute malnutrition is a life-threatening form of under-nutrition that occurs primarily in third world countries. Kwashiorkor is an aggressive form of severe acute malnutrition characterized by generalized edema, skin rash, and anorexia; it is a consequence of deficiencies in nutrient intake, along with unknown environmental factors.⁹⁷ Recent studies have suggested that an immature gut microbiome contributes to development of kwashiorkor as in children with this disease the microbiome failed to mature over time and was characterized by a reduced overall gene content.⁹⁸ Ready-to-use therapeutic food (RUTF), a homogenous mixture of lipid-rich and water-soluble food components, has been used to treat kwashiorkor. RUTF not only reduces symptoms of kwashiorkor but also has significant effects on the gut microbiota.

Kwashiorkor-like features can be induced in gnotobiotic mice by transplantation of frozen stool samples from children with kwashiorkor and then placing the mice on a sterilized typical Malawian diet. Mice that developed kwashiorkor-like symptoms had higher numbers of *Bilophila wadsworthia* and *Clostridium innocuum* than mice fed a Malawian diet that did not develop kwashiorkor-like symptoms. These findings are of interest because *Bwadsworthii* has been identified as a potential pathobiont in other studies.⁶⁰

The findings have also been supported by studies of children in Bangladesh. In these children, severe acute malnutrition was also associated with an immaturity of the microbiota.⁹⁹ Importantly, nutritional interventions produced partial clinical improvement and only partially ameliorated microbiota immaturity. An immature microbiota was also observed in children with less-severe malnutrition and correlated with anthropometric parameters. In a study of the effects of adjunct antibiotic therapy in children with kwashiorkor,¹⁰⁰ the combination of RUFT and antibiotics was superior to that of RUTF and placebo in improving recovery and reducing mortality. Despite various explanations for this outcome (e.g. the immunocompromised state of kwashiorkor children), the findings indicate that the intestinal microbiota make important contributions to certain forms of malnutrition.

So, a balanced diet that continuously includes diverse nutrients, such as SCFAs and AhR ligands, might be a prerequisite for a potent immune response, a healthy microbiota, and intact barrier function. Little is understood about how food, the immune system, and the intestinal microbiota interact, especially under conditions of under-nutrition. One consequence of prolonged under-nutrition appears to be inflammatory disease, which could develop because the immature microbiota lacks the ability to sense and respond to metabolites such as SCFAs or nicotinic acid, nutrients such as AhR ligands, and tryptophan or retinoic acids. Microbial responses to factors such as bile acids could also be impaired in the immature microbiota, leading to expansion of pathobionts and inflammation. Similar changes in the microbiome might be associated with other diseases characterized by cachexia and malnutrition.

Conclusions

There is a fascinating relationship among food, immunity, and the microbiota. Many dietary components affect these interactions. We do not know how dietary modification of commensals affects the core microbiome, or how this produces functional consequences. We know that bacterial metabolites such as SCFAs, metabolites generated from food by bacteria (TMAO), and dietary components alone affect the functions of many human systems and tissues.

Many commensals and their metabolites are required to obtain nutrients from food and maintain gut health and homeostasis. These are likely to have evolved as we adapted to new dietary and microbial signals, resulting in a complex mutualistic network between human cells and microbes. This network is a challenge to study, due to technical limitations. Nonetheless, the field of microbiota research is growing rapidly.

Studies of BD have suggested that analysis of stool samples might not be adequate to study the intestinal microbiome—rectum biopsy samples seem to be more appropriate.¹⁰¹ This could also hold true for many other diseases in which currently the microbiome is investigated. Furthermore, as we associate changes in the microbiome with features of diseases, it is not clear which causes the other. In studies of obesity or malnutrition, it is not clear whether associated changes in the microbiota occurred before, during, or as a result of these disorders.

Interventional studies have established that dietary factors have strong effects on the microbiota. However, it will be important to optimize clinical studies to gain deeper mechanistic insights. Such studies could lead to development of functional foods, with beneficial and even therapeutic effects on the microbiota and immune system. Foods might one day be used in clinical medicine to prevent and treat diseases. **The effects of food on the microbiota and immune system is one of the most exciting areas of science—we now**

know that microbiota-derived and dietary factors operate together to determine gut health and beyond. You are what you eat is finally supported by scientific evidence.

Table 1: Effects of various diets on microbiota and immunity

INFLAMMATORY	Foods (Food Components)	Microbiota-dependent	Involved pathways	Effect on Immunity
	red meat, eggs, milk (contain phosphatidylcholine, L-carnitine)	+ ¹	TMA TMAO	atherosclerosis ↑ (pro-inflammatory cytokines, forward cholesterol transport)
	high fat diet	+ ¹	intestinal permeability ↑ TLRs	endotoxemia intestinal cytokine expression ↑ intestinal and systemic inflammation ↑
	milk-derived fat	+ ²	expansion of pathobionts (e.g. <i>Bilophilawadsworthia</i>)	pro-inflammatory cytokines ↑ Th1-driven inflammation ↑
	salt	?	p38 / MAPK pathway	Th17-driven inflammation ↑

ANTI-INFLAMMATORY	Foods (Food Components)	Microbiota-dependent	Involved pathways	Effect on Immunity
	cruciferous vegetables (carbazoles)	+ ²	AhR ligands	IL-22 ↑, maintenance of intraepithelial lymphocytes and innate lymphoid cells
	vegetables, fish (tryptophan)	+ ²	AhR ligands ³ GPCRs ⁴	IL-22 ↑, mucosal protection from inflammation
	soluble fiber (complex carbohydrates)	+ Generation of SCFA	GPCRs (Gpr41, Gpr43, Gpr109a)	mucus production ↑ IgA production ↑ pro-inflammatory cytokines ↓ Tregs ↑
	mediterranean diet (enriched in ω-3 fatty acids)	?	Gpr120	pro-inflammatory cytokines ↓

¹ either shown in germfree mice or after prolonged antibiotic therapy

² diet results in an altered microbiota

³ tryptophan metabolized by microbiota (e.g. *Lactobacilli*) to indole-3 aldehyde and kynurenine (both AhR ligands)

⁴ tryptophan metabolites kynurenine and niacin bind to GPCRs

Abbreviations

AhR aryl hydrocarbon receptor
 GPCRs G-protein coupled receptors
 MAPK mitogen-activated protein kinase
 SCFA short chain fatty acids
 Th T helper cell
 TLRs Toll like receptors
 TMA Trimethylamine
 TMAO Trimethylamine N-Oxide
 Tregs regulatory T cells

ACCEPTED MANUSCRIPT

Figure Legends

Figure 1. Network of Food, Immunity, and the Microbiota

Foods, mainly plant-, fruit-, and animal-derived carbohydrates and proteins and fats, rapidly affect the composition and metabolic capacities of our commensal microbiota (green arrow). From the perspective of the microbiota, altered environmental conditions place selective pressure on various species, leading to competition for the most fit to survive and replicate. Microbes produce signals that manipulate the host's eating behavior, generating cravings or dysphoria for certain nutrients (dashed blue arrow). The microbiota signals either through microbiota-immanent molecules, such as TLR ligands or inflammasomes or NOD activators, or through products derived from its enzymatic machinery such as SCFAs or TMA (black arrow). From the perspective of the host, the food supply is scarce and linked with geographical, seasonal, and ethnical parameters. Evolution has produced a highly optimized mutualistic system in which the maximum capacity of energy is extracted from a given amount of food while intestinal homeostasis is maintained. Consequently, animals have evolved mechanisms to modify the microbiota for their own benefit, such as via the mucus barrier and AMPs. Many of the involved mechanisms are produced by the intestinal mucosal immune system (red arrow). It is important to mention that the intestinal immune system can maintain a state of local and systemic unresponsiveness towards orally administered food and microbial antigens. Finally, certain food-derived signals are able to directly engage with host receptors such as the aryl hydrocarbon receptor (green dashed line).

Abbreviations: AMPs, anti-microbial peptides; NOD, nucleotide oligomerization domain; SCFAs, short-chain fatty acids; TLR, toll-like receptor; TMA, trimethylamine

Figure 2. Inflammatory Mechanisms of Food Components

(A) Certain dietary components can directly activate inflammatory pathways. Free fatty acids (FFA) induce lysosomal instability, leading to release of cathepsin B and activation of NF κ B. Palmitic acid activates IL1 β and IL18 through a pathway involving TLR2 and the NALP3

inflammasome. Palmitic acid also increases intestinal permeability, resulting in endotoxemia in the portal and systemic circulation. Sodium chloride enhances differentiation of IL17-producing CD4⁺ T cells (T-helper 17 cells) through a pathway involving p38 MAPK, NFAT5, and SGK1.

(B) Other dietary components induce inflammation indirectly, after modification by the commensal microflora. Ingested PC or L-carnitine is converted to TMA by bacterial enzymes. TMA is further processed by hepatic flavin monooxygenases to TMAO, which promotes atherosclerosis and activates macrophages.

(C) Certain diets alter the intestinal microbiota to one that promotes inflammation. In genetically susceptible animals (those with defects in inflammasome function or animals that overexpress CEACAMs), these alterations to the microbiota can promote initiation or aggravation of intestinal inflammation, via various mechanisms. Milk-derived saturated fats promote taurin-conjugation of bile acids—important sources of organic sulfur, supporting the development of sulphite-reducing pathobionts such as *Bilophila wadsworthia*. These can promote inflammation.

Abbreviations: CEACAM, carcinoembryonic antigen-related cell adhesion molecule; FMO, flavin monooxygenases; IL, interleukin; NALP3, NOD-like receptor family, pyrin domain containing 3; NFAT5, nuclear factor of activated T-cells 5; NF- κ B, nuclear factor kappa B; SGK1, serine/threonine-protein kinase 1; Th, T helper cell

Figure 3. Anti-inflammatory Effects of Food Components

(A) The aryl hydrocarbon receptor (AhR) provides an important link between the intestinal immune system and food-derived ligands. AhR activating ligands include indolo[3,2-b]carbazole or 6-formylindolo[3,2-b]carbazole, which come from cruciferous vegetables, flavonoids, and polyphenols, (B) as well as bacterial-derived molecules, such as phenazines and naphthoquinone phthalocyanine, and microbial metabolic products such as 1,4-dihydroxy-2-naphthoic acid. AhR ligands activate chaperone-bound AhRs, which dimerize with the AhR nuclear translocator (Arnt) to regulate gene expression. AhR signaling is required for the generation and maintenance of intestinal immune cells including specialized intraepithelial

lymphocytes and CD4-ROR γ δ ⁺ innate lymphoid cells. AhR-induced production of IL22 could have immunomodulatory and metabolic effects. (C) Tryptophan is another important anti-inflammatory molecule in food. Its uptake is regulated by intestinal ACE2 (independent of its functions in the renin-angiotensin system). Tryptophan is converted to indole-3-aldehyde (another ligand of AhR) by bacterial enzymes. Tryptophan is required for generation of nicotinamide (also vitamin B3 or niacin). Nicotinamide can activate the mTOR pathway, including p70S6 kinase and anti-microbial peptides, to produce anti-inflammatory effects. Within the cell, tryptophan is converted to kynurenine (another AhR ligand) by indoleamine 2,3-dioxygenase (IDO). (D) Soluble dietary fiber (complex carbohydrates, CCH) is cleaved into SCFAs by bacterial glycoside hydrolases. The SCFAs acetate, propionate, and butyrate have anti-inflammatory effects. SCFAs bind GPCRs such as GPR41, GPR43, or GPR109A, which activate the transcription factor arrestin- β 2. Interestingly, GPCRs can be activated by other ligands such as niacin (GPR109A) and Ω -3fattyacids (GPR120). Butyrate is a natural inhibitor of the histone deacetylases 6 and 9, and could promote development of peripheral regulatory T cells through epigenetic mechanisms.

Abbreviations: AA, amino acids; ACE2, angiotensin-converting enzyme; FOXP3, forkhead box P3; GPCRs, G-protein coupled receptors; HA/Nam, nicotinamide; HDAC, histone deacetylase; IE, intraepithelial; ILCs, intestinal lymphoid cells; mTOR, mechanistic target of Rapamycin; Treg, regulatory T cells

References

1. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. *Science* 2005;308:1635-8.
2. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. *Nature* 2010;464:59-65.
3. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. *Nature* 2009;457:480-4.
4. Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. *Nature* 2012;486:222-7.
5. Claesson MJ, Jeffery IB, Conde S, et al. Gut microbiota composition correlates with diet and health in the elderly. *Nature* 2012;488:178-84.
6. Dominguez-Bello MG, Costello EK, Contreras M, et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. *Proc Natl Acad Sci U S A* 2010;107:11971-5.
7. Yoshioka H, Iseki K, Fujita K. Development and differences of intestinal flora in the neonatal period in breast-fed and bottle-fed infants. *Pediatrics* 1983;72:317-21.
8. Lievin V, Peiffer I, Hudault S, et al. Bifidobacterium strains from resident infant human gastrointestinal microflora exert antimicrobial activity. *Gut* 2000;47:646-52.
9. Koenig JE, Spor A, Scalfone N, et al. Succession of microbial consortia in the developing infant gut microbiome. *Proc Natl Acad Sci U S A* 2011;108 Suppl 1:4578-85.
10. Fukuda S, Toh H, Hase K, et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. *Nature* 2011;469:543-7.

11. Wu GD, Chen J, Hoffmann C, et al. Linking long-term dietary patterns with gut microbial enterotypes. *Science* 2011;334:105-8.
12. Veldhoen M, Brucklacher-Waldert V. Dietary influences on intestinal immunity. *Nat Rev Immunol* 2012;12:696-708.
13. Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. *N Engl J Med* 2013;368:1279-90.
14. Moschen AR, Wieser V, Tilg H. Dietary Factors: Major Regulators of the Gut's Microbiota. *Gut Liver* 2012;6:411-6.
15. Albenberg LG, Wu GD. Diet and the intestinal microbiome: associations, functions, and implications for health and disease. *Gastroenterology* 2014;146:1564-72.
16. Turnbaugh PJ, Ridaura VK, Faith JJ, et al. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. *Science translational medicine* 2009;1:6ra14.
17. David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. *Nature* 2014;505:559-63.
18. Cox LM, Yamanishi S, Sohn J, et al. Altering the Intestinal Microbiota during a Critical Developmental Window Has Lasting Metabolic Consequences. *Cell* 2014;158:705-21.
19. De Filippo C, Cavalieri D, Di Paola M, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. *Proc Natl Acad Sci* 2010;107:14691-6.
20. Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. *Nature* 2011;473:174-80.

21. Zimmer J, Lange B, Frick JS, et al. A vegan or vegetarian diet substantially alters the human colonic faecal microbiota. *Eur J Clin Nutr* 2012;66:53-60.
22. Hildebrandt MA, Hoffmann C, Sherrill-Mix SA, et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. *Gastroenterology* 2009;137:1716-24 e1-2.
23. Walker AW, Ince J, Duncan SH, et al. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. *ISME J* 2011;5:220-30.
24. Clarke SF, Murphy EF, O'Sullivan O, et al. Exercise and associated dietary extremes impact on gut microbial diversity. *Gut* 2014; 63:1913-20.
25. Claesson MJ, Cusack S, O'Sullivan O, et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. *Proc Natl Acad Sci* 2011;108 Suppl 1:4586-91.
26. Hanage WP. Microbiology: Microbiome science needs a healthy dose of scepticism. *Nature* 2014;512:247-8.
27. Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature* 2006;444:1027-31.
28. Tilg H, Moschen AR, Kaser A. Obesity and the microbiota. *Gastroenterology* 2009;136:1476-83.
29. Cotillard A, Kennedy SP, Kong LC, et al. Dietary intervention impact on gut microbial gene richness. *Nature* 2013;500:585-8.
30. Tremaroli V, Backhed F. Functional interactions between the gut microbiota and host metabolism. *Nature* 2012;489:242-9.

31. Cox LM, Blaser MJ. Pathways in microbe-induced obesity. *Cell Metab* 2013;17:883-94.
32. Tilg H, Kaser A. Gut microbiome, obesity, and metabolic dysfunction. *J Clin Invest* 2011;121:2126-32.
33. Vermeire S, Ferrante M, Rutgeerts P. Recent advances: Personalised use of current Crohn's disease therapeutic options. *Gut* 2013;62:1511-5.
34. Sartor RB. Microbial influences in inflammatory bowel diseases. *Gastroenterology* 2008;134:577-94.
35. Park Y, Subar AF, Hollenbeck A, et al. Dietary fiber intake and mortality in the NIH-AARP diet and health study. *Arch Intern Med* 2011;171:1061-8.
36. Vos MB, Lavine JE. Dietary fructose in nonalcoholic fatty liver disease. *Hepatology* 2013;57:2525-31.
37. Sapp V, Gaffney L, EauClaire SF, et al. Fructose leads to hepatic steatosis in zebrafish that is reversed by mTOR inhibition. *Hepatology* 2014.
38. Mozaffarian D, Fahimi S, Singh GM, et al. Global sodium consumption and death from cardiovascular causes. *N Engl J Med* 2014;371:624-34.
39. Kleinewietfeld M, Manzel A, Titze J, et al. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. *Nature* 2013;496:518-22.
40. Nagel G, Weinmayr G, Kleiner A, et al. Effect of diet on asthma and allergic sensitisation in the International Study on Allergies and Asthma in Childhood (ISAAC) Phase Two. *Thorax* 2010;65:516-22.
41. Kau AL, Ahern PP, Griffin NW, et al. Human nutrition, the gut microbiome and the immune system. *Nature* 2011;474:327-36.

42. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. *Nature* 2011;472:57-63.
43. al-Waiz M, Mikov M, Mitchell SC, et al. The exogenous origin of trimethylamine in the mouse. *Metabolism* 1992;41:135-6.
44. Lang DH, Yeung CK, Peter RM, et al. Isoform specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes: selective catalysis by FMO3. *Biochem Pharmacol* 1998;56:1005-12.
45. Bennett BJ, de Aguiar Vallim TQ, Wang Z, et al. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. *Cell Metab* 2013;17:49-60.
46. Martin FP, Wang Y, Sprenger N, et al. Probiotic modulation of symbiotic gut microbial-host metabolic interactions in a humanized microbiome mouse model. *Mol Syst Biol* 2008;4:157.
47. Brugere JF, Borrel G, Gaci N, et al. Archaeobiotics: proposed therapeutic use of archaea to prevent trimethylaminuria and cardiovascular disease. *Gut Microbes* 2014;5:5-10.
48. Tang WH, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. *N Engl J Med* 2013;368:1575-84.
49. Wang Z, Tang WH, Buffa JA, et al. Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. *Eur Heart J* 2014;35:904-10.
50. Hartiala J, Bennett BJ, Tang WH, et al. Comparative genome-wide association studies in mice and humans for trimethylamine N-oxide, a proatherogenic metabolite of choline and L-carnitine. *Arterioscler Thromb Vasc Biol* 2014;34:1307-13.

51. Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. *Nat Med* 2013;19:576-85.
52. Calder PC. Fatty acids and inflammation: the cutting edge between food and pharma. *Eur J Pharmacol* 2011;668 Suppl 1:S50-8.
53. Lee JY, Sohn KH, Rhee SH, et al. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. *J Biol Chem* 2001;276:16683-9.
54. Huang S, Rutkowsky JM, Snodgrass RG, et al. Saturated fatty acids activate TLR-mediated proinflammatory signaling pathways. *J Lipid Res* 2012;53:2002-13.
55. Pendyala S, Walker JM, Holt PR. A high-fat diet is associated with endotoxemia that originates from the gut. *Gastroenterology* 2012;142:1100-1101 e2.
56. Galli C, Calder PC. Effects of fat and fatty acid intake on inflammatory and immune responses: a critical review. *Ann Nutr Metab* 2009;55:123-39.
57. Ding S, Chi MM, Scull BP, et al. High-fat diet: bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse. *PLoS One* 2010;5:e12191.
58. Ji Y, Sun S, Goodrich JK, et al. Diet-induced alterations in gut microflora contribute to lethal pulmonary damage in TLR2/TLR4-deficient mice. *Cell Rep* 2014;8:137-49.
59. Ghosh S, Molcan E, DeCoffe D, et al. Diets rich in n-6 PUFA induce intestinal microbial dysbiosis in aged mice. *Br J Nutr* 2013;110:515-23.
60. Devkota S, Wang Y, Musch MW, et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in *Il10*^{-/-} mice. *Nature* 2012;487:104-8.

61. Myles IA, Fontecilla NM, Janelsins BM, et al. Parental dietary fat intake alters offspring microbiome and immunity. *J Immunol* 2013;191:3200-9.
62. Martinez-Medina M, Denizot J, Dreux N, et al. Western diet induces dysbiosis with increased *E coli* in CEABAC10 mice, alters host barrier function favouring AIEC colonisation. *Gut* 2014;63:116-24.
63. Li Y, Innocentin S, Withers DR, et al. Exogenous stimuli maintain intraepithelial lymphocytes via aryl hydrocarbon receptor activation. *Cell* 2011;147:629-40.
64. Kiss EA, Vonarbourg C, Kopfmann S, et al. Natural aryl hydrocarbon receptor ligands control organogenesis of intestinal lymphoid follicles. *Science* 2011;334:1561-5.
65. Julliard W, Fechner JH, Mezrich JD. The aryl hydrocarbon receptor meets immunology: friend or foe? A little of both. *Front Immunol* 2014;5:458.
66. Monteleone I, Rizzo A, Sarra M, et al. Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. *Gastroenterology* 2011;141:237-48, 248 e1.
67. Wang X, Ota N, Manzanillo P, et al. Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. *Nature* 2014; 514:237-41.
68. Stefka AT, Feehley T, Tripathi P, et al. Commensal bacteria protect against food allergen sensitization. *Proc Natl Acad Sci U S A* 2014; 111:13145-50.
69. Shin JH, Zhang L, Murillo-Sauca O, et al. Modulation of natural killer cell antitumor activity by the aryl hydrocarbon receptor. *Proc Natl Acad Sci U S A* 2013;110:12391-6.

70. Fukumoto S, Toshimitsu T, Matsuoka S, et al. Identification of a probiotic bacteria-derived activator of the aryl hydrocarbon receptor that inhibits colitis. *Immunol Cell Biol* 2014;92:460-5.
71. Moura-Alves P, Fae K, Houthuys E, et al. AhR sensing of bacterial pigments regulates antibacterial defence. *Nature* 2014;512:387-92.
72. Zelante T, Iannitti RG, Cunha C, et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. *Immunity* 2013;39:372-85.
73. Hashimoto T, Perlot T, Rehman A, et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. *Nature* 2012;487:477-81.
74. Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. *Trends Immunol* 2013;34:137-43.
75. Opitz CA, Litzemberger UM, Sahm F, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. *Nature* 2011;478:197-203.
76. Wang HK, Yeh CH, Iwamoto T, et al. Dietary flavonoid naringenin induces regulatory T cells via an aryl hydrocarbon receptor mediated pathway. *J Agric Food Chem* 2012;60:2171-8.
77. Mohammadi-Bardbori A, Bengtsson J, Rannug U, et al. Quercetin, resveratrol, and curcumin are indirect activators of the aryl hydrocarbon receptor (AHR). *Chem Res Toxicol* 2012;25:1878-84.
78. Brown AJ, Goldsworthy SM, Barnes AA, et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. *J Biol Chem* 2003;278:11312-9.

79. Le Poul E, Loison C, Struyf S, et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. *J Biol Chem* 2003;278:25481-9.
80. Wrzosek L, Miquel S, Noordine ML, et al. *Bacteroides thetaiotaomicron* and *Faecalibacterium prausnitzii* influence the production of mucus glycans and the development of goblet cells in the colonic epithelium of a gnotobiotic model rodent. *BMC Biol* 2013;11:61.
81. Tan J, McKenzie C, Potamitis M, et al. The role of short-chain fatty acids in health and disease. *Adv Immunol* 2014;121:91-119.
82. Inan MS, Rasoulpour RJ, Yin L, et al. The luminal short-chain fatty acid butyrate modulates NF-kappaB activity in a human colonic epithelial cell line. *Gastroenterology* 2000;118:724-34.
83. Elinav E, Strowig T, Kau AL, et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. *Cell* 2011;145:745-57.
84. Thorburn AN, Macia L, Mackay CR. Diet, metabolites, and "western-lifestyle" inflammatory diseases. *Immunity* 2014;40:833-42.
85. Oh DY, Talukdar S, Bae EJ, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. *Cell* 2010;142:687-98.
86. Maslowski KM, Vieira AT, Ng A, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. *Nature* 2009;461:1282-6.
87. Endres S, Ghorbani R, Kelley VE, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. *N Engl J Med* 1989;320:265-71.

88. Singh N, Gurav A, Sivaprakasam S, et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. *Immunity* 2014;40:128-39.
89. Zandi-Nejad K, Takakura A, Jurewicz M, et al. The role of HCA2 (GPR109A) in regulating macrophage function. *FASEB J* 2013;27:4366-74.
90. Lukasova M, Malaval C, Gille A, et al. Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. *J Clin Invest* 2011;121:1163-73.
91. Furusawa Y, Obata Y, Fukuda S, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. *Nature* 2013;504:446-50.
92. Arpaia N, Campbell C, Fan X, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. *Nature* 2013;504:451-5.
93. Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. *Science* 2013;341:569-73.
94. Chang PV, Hao L, Offermanns S, et al. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. *Proc Natl Acad Sci U S A* 2014;111:2247-52.
95. Trompette A, Gollwitzer ES, Yadava K, et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. *Nat Med* 2014;20:159-66.
96. Tannahill GM, Curtis AM, Adamik J, et al. Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. *Nature* 2013;496:238-42.

97. Gordon JI, Dewey KG, Mills DA, et al. The human gut microbiota and undernutrition. *Sci Translat Med* 2012;4:137ps12.
98. Smith MI, Yatsunenko T, Manary MJ, et al. Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. *Science* 2013;339:548-54.
99. Subramanian S, Huq S, Yatsunenko T, et al. Persistent gut microbiota immaturity in malnourished Bangladeshi children. *Nature* 2014;510:417-21.
100. Trehan I, Goldbach HS, LaGrone LN, et al. Antibiotics as part of the management of severe acute malnutrition. *New Engl J Med* 2013;368:425-35.
101. Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn's disease. *Cell Host Microbe* 2014;15:382-92.

